|
|
|
|
|
|
|
|
|
Webinar: From iPSC Starting Material to Scalable GMP Manufacturing
|
Developing scalable, high-quality iPSC sources can be complex as cell therapy programs move toward clinical manufacturing. This webinar explores an integrated approach combining GMP iPSC lines, working cell banks, GMP-compatible media, and standardized expansion protocols. Learn how this coordinated system can simplify process development, support reproducible high-volume iPSC feed streams, scale to billions of cells, and enable downstream differentiation. Click here to learn more.
|
|
|
|
|
|
|
|
Custom Assemblies For Viral Vector Manufacturing
|
|
Case Study | Sanisure
|
Meeting tight production timelines requires planning and supply chain resilience. Learn how manufacturing coordination supported viral vector production and delivery under pressure.
|
|
|
|
|
|
Enhancing AAV Production Performance And Economics
|
|
Application Note | Touchlight
|
Enzymatically produced dbDNA offers safer, faster, and more scalable AAV manufacturing by reducing costs, improving full capsid yields, and enabling high‑fidelity, bacteria‑free DNA production.
|
|
|
|
|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma
|
Praise to the RNA innovators, and our innovative service providers. You’ve brought us a long way. Still, that progress hasn’t necessarily made it easier to strategize the outsourcing of specific RNA-based projects. We’ve expanded development programs therapeutically and dialed up nuanced production requirements. So the current question is what will the RNA outsourcing ecosystem look like a few years from now? Here’s some expert analysis.
|
|
|
|
|
|
|
|
A Conversation with Charles Gore, Medicines Patent Pool
|
Turning patented biomedical discoveries into affordable, widely available treatments requires aligned partnerships between innovator pharma and regional generic manufacturers. In this episode of Outsourcing Against the Outbreak, Charles Gore, Executive Director of the Medicines Patent Pool (MPP), breaks down how voluntary licensing models expand access across low- and middle-income markets.
|
|
|
|
|
|
How Smart Outsourcing Is Accelerating ATMP Development
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma
|
Innovation requires new thinking and approaches. It also heightens the need for disciplined execution. With ATMP development – as well as with any program – starting out on a path lined with outsourcing principles may prove your greatest competitive advantage. A discussion from Chief Editor Louis Garguilo.
|
|
|
|
INDUSTRY INSIGHTS CONTINUED
|
|
|
|
|
|
|
|
Boosting Plasmid Yield & Integrity
|
|
Poster | By Shrey Amin, Ssempa Kisaalita, Sneha Vilayur, et al., ProBio
|
This e. coli platform boosts plasmid DNA yield, preserves ITR integrity, and reduces variability, enabling scalable, cost-effective manufacturing for gene therapy and vaccine applications.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Crucial Role Of Apheresis In Cellular Therapies
|
|
Webinar | Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises
|
Focusing on quality, the presenters will discuss the importance of adhering to collection protocols and the real-world effects on treatment outcomes.
|
|
|
|
|
|
|
|
|
|
|
|
Enabling Success in Cell & Gene Therapy — October 29 at 11:00 a.m. ET
|
Explore the technologies, capabilities, and scale-up strategies advancing cell and gene therapy manufacturing. Leading CGT CDMOs will share insights on process development, technology transfer, clinical supply, and commercial readiness, helping sponsors evaluate potential partners and navigate the unique challenges of advanced therapy manufacturing. Learn more.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE
|
|
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
|
